AI Article Synopsis
- EBV is linked to various types of lymphomas, including non-Hodgkin and Hodgkin subtypes, and its role in cancer development and the tumor environment is still being explored.
- Both the International Consensus Classification and WHO-HAEM5 emphasize the unique characteristics of EBV-related lymphoproliferative disorders.
- Recent advancements have been made in understanding EBV, its effects on the immune response, and using it for targeted therapies and disease monitoring.
Article Abstract
Epstein-Barr virus (EBV)-associated lymphomas cover a range of histological B- and T-cell non-Hodgkin and Hodgkin lymphoma subtypes. The role of EBV on B-cell malignant pathogenesis and its impact on the tumour microenvironment are intriguing but incompletely understood. Both the International Consensus Classification (ICC) and 5th Edition of the World Health Organization (WHO-HAEM5) proposals give prominence to the distinct clinical, prognostic, genetic and tumour microenvironmental features of EBV in lymphoproliferative disorders. There have been major advances in our biological understanding, in how to harness features of EBV and its host immune response for targeted therapy, and in using EBV as a method to monitor disease response. In this article, we showcase the latest developments and how they may be integrated to stimulate new and innovative approaches for further lines of investigation and therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bjh.19255 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!